|
1）Mizisin AP, Weerasuriya A. Homeostatic regula-tion of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol. 2011; 121: 291-312
|
|
|
|
2）Kanda T. Biology of the blood-nerve barrier and its alteration in immune-mediated neuropathies. J Neurol Neurosurg Psychiatry. 2012; 83: In press
|
|
|
|
|
|
3）Engelhardt B. T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol. 2010; 1: 79-93
|
|
|
|
|
4）Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2011; 1812: 252-64
|
|
|
|
|
|
5）de Andres C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and func-tional impairment of dendritic cells during nata-lizumab therapy in patients with multiple scle-rosis. PLoS One. 2012; 7: e34103
|
|
|
|
|
|
6）神田 隆. 血液神経関門Update. Brain and Nerve. 2011; 63: 557-69
|
|
|
|
|
7）Kanda T, Iwasaki T, Yamawaki M, et al. Isolation and culture of bovine endothelial cells of endo-neurial origin. J Neurosci Res. 1997; 49: 769-77
|
|
|
|
|
|
8）Sano Y, Shimizu F, Nakayama H, et al. Endo-thelial cells constituting blood-nerve barrier have highly specialized characteristics as barrier-forming cells. Cell Struct Funct. 2007; 32: 139-47
|
|
|
|
|
9）Shimizu F, Sano Y, Maeda T, et al. Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol. 2008; 217: 388-99
|
|
|
|
|
|
10）Shimizu F, Sano Y, Abe M, et al. Peripheral nerve pericytes modify blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol. 2011; 226: 255-66
|
|
|
|
|
|
11）Shimizu F, Sano Y, Haruki H, et al. Advanced glycation endo-products induce basement mem-brane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-beta and VEGF by pericytes. Diabetologia. 2011; 54: 1517-26
|
|
|
|
|
|
12）Yosef N, Xia RH, Ubogu EE. Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells. J Neuropathol Exp Neurol. 2010; 69: 82-97
|
|
|
|
|
|
13）Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leuko-encephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010; 67: 923-30
|
|
|
|
|
|
14）Kanda T, Hayashi H, Tanabe H, et al. A fulmi-nant case of Guillain-Barre syndrome: topographic and fibre size related analysis of demyelinating changes. J Neurol Neurosurg Psychiatry. 1989; 52: 857-64
|
|
|
|
|
|
15）Kanda T, Usui S, Beppu H, et al. Blood-nerve barrier in IgM paraproteinemic neuropathy: a clinicopathologic assessment. Acta Neuropathol. 1998; 95: 184-92
|
|
|
|
|
|
16）Kanda T, Yamawaki M, Iwasaki T, et al. Glycosphingolipid antibodies and blood-nerve barrier in autoimmune demyelinative neuropathy. Neurology. 2000; 54: 1459-64
|
|
|
|
|
|
17）Kanda T, Numata Y, Mizusawa H. Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1. J Neurol Neurosurg Psychiatry. 2004; 75: 765-9
|
|
|
|
|
|
18）Ohara S, Ikuta F. On the occurrence of the fenestrated vessels in Wallerian degeneration of the peripheral nerve. Acta Neuropathol. 1985; 68: 259-62
|
|
|
|
|
|
19）Sixt M, Engelhardt B, Pausch F, et al. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol. 2001; 153: 933-46
|
|
|
|
|
|
20）Wu C, Ivars F, Anderson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med. 2009; 15: 519-27
|
|
|
|
|
|
21）Low P, Marchand G, Knox F, Dyck PJ. Measure-ment of endoneurial fluid pressure with poly-ethylene matrix capsules. Brain Res. 1977; 122: 373-7
|
|
|
|
|
|
22）Low PA. In vitro study of acute elevations of endoneurial pressure in mammalian peripheral nerve sheath. Exp Neurol. 1981; 74: 160-9
|
|
|
|
|
|
23）Myers RR, Murakami H, Powell HC. Reduced nerve blood flow in edematous neuropathies: a biomechanical mechanism. Microvasc Res. 1986; 32: 145-51
|
|
|
|
|
|
24）Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhe-sion cascade updated. Nat Rev Immunol. 2007; 7: 678-89
|
|
|
|
|
|
25）Yosef N, Ubogu EE. Alpha(M) beta(2) -integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barre syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. J Cell Physiol. 2012; 227: 3857-75
|
|
|
|
|
|
26）Kanda T, Yamawaki M, Ariga T, Yu R. Interleukin 1 beta up-regulates the expression of sulfoglucuro-nosyl paragloboside, a ligand for L-selectin, in brain microvascular endothelial cells. Proc Natl Acad Sci U S A. 1995; 92: 7897-901
|
|
|
|
|
|
27）Wong D, Prameya R, Dorovini-Zis K. In vitro adhesion and migration of T lymphocytes across monolayers of human microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1. J Neuropathol Exp Neurol. 1999; 58: 138-52
|
|
|
|
|
|
28）Joshi A, Bauer R, Kuebler P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006; 46: 10-20
|
|
|
|
|
|
29）Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Coch-rane Database Syst Rev. 2011(10): CD007621
|
|
|
|
|
|
30）Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. J Neuropathol Exp Neurol. 2012; 71: 604-17
|
|
|
|
|
|
31）Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008; 9: 137-45
|
|
|
|
|
|
32）Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009; 132(Pt 12): 3329-41
|
|
|
|
|
|
33）Kashiwamura Y, Sano Y, Abe M, et al. Hydro-cortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res. 2011; 36: 849-55
|
|
|
|
|
|
34）Yosef N, Ubogu EE. GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvasc Res. 2012; 83: 298-310
|
|
|
|
|
|
35）Fisher M. Pericyte signaling in the neurovascular unit. Stroke. 2009; 40(3 Suppl): S13-5
|
|
|
|
|
|
36）Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neu-ronal phenotype in the adult brain and during brain aging. Neuron. 2010; 68: 409-27
|
|
|
|
|
|
37）Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010; 468: 557-61
|
|
|
|
|